Author Affiliations: HIV/AIDS and Retrovirology Branch, Division of AIDS, STD and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC), Atlanta, Ga (Dr Chapman); Laboratory of Immunology and Virology, Division of Cellular and Gene Therapies, Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Md (Dr Bloom).
Contempo Updates Section Editor: Alice T.
D. Hughes, MD, Fishbein Fellow.
The remarkable half-century transition of whole organ transplantation
from experimental intervention to standard clinical practice has resulted
in a growing disparity between the number of persons who could potentially
benefit from allotransplants and the availability of transplantable human
organs.1 This disparity inspired initial attempts
to explore alternative therapies for organ failure, among them xenotransplantation,
which involves the use of living, nonhuman animal tissues in humans.
Chapman LE, Bloom ET. Clinical Xenotransplantation. JAMA. 2001;285(18):2304-2306. doi:10.1001/jama.285.18.2304